Entera Bio Ltd.: appoints director Laura Hamill

What happened

• The company announced that on Oct 6, 2026 the board appointed Laura Hamill as a Class I director of Entera Bio Ltd., effective Dec 1, 2026. Ms. Hamill will serve until the company’s 2027 Annual Meeting of Shareholders and until her successor is elected and qualified, or until earlier death, resignation, retirement, disqualification or removal.
• The filing states Ms. Hamill, age 62, has more than 35 years of commercial leadership experience, most recently served as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc., and spent nearly 20 years at Amgen Inc. She currently serves on the boards of Jazz Pharmaceuticals plc, BB Biotech AG, and Fate Therapeutics, Inc. The board appointed her to the audit committee and the corporate governance and nomination committee, each effective Dec 1, 2026.
• The filing also states that on Oct 6, 2026 Yonatan Malca notified the board he would step down as a director, effective Dec 1, 2026, and that his departure was not the result of any disagreement with the company on any matter relating to the company’s operations, policies, or practices.

Key details

• Appointment date: Oct 6, 2026; effective date of director service: Dec 1, 2026.
• Committee appointments: audit committee and corporate governance and nomination committee, effective Dec 1, 2026.
• Term: will serve until the 2027 Annual Meeting of Shareholders or until a successor is elected and qualified.
• Compensation: Ms. Hamill will participate in the company’s standard non-employee director compensation arrangements approved by shareholders in Jul 2026, including annual cash payments and annual equity grants under the 2018 Equity Incentive Plan.
• Independence and transaction disclosures: the board determined Ms. Hamill is independent under applicable SEC and Nasdaq rules; since the beginning of the company’s last fiscal year, there were no transactions requiring disclosure under Item 404(a) of Regulation S-K involving Ms. Hamill.

Why it may matter

• The filing reports Item 5.02 (departure of directors or certain officers; election or appointment of directors; compensatory arrangements of certain officers) and Item 7.01 (Regulation FD disclosure). Item 5.02 covers director appointments, departures, committee assignments, independence determinations, and director compensation arrangements.
• This filing does not show why the insider traded or why the company acted.